0001104659-21-151823.txt : 20211220
0001104659-21-151823.hdr.sgml : 20211220
20211220174915
ACCESSION NUMBER: 0001104659-21-151823
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211220
FILED AS OF DATE: 20211220
DATE AS OF CHANGE: 20211220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goel Shubh
CENTRAL INDEX KEY: 0001787942
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32295
FILM NUMBER: 211506282
MAIL ADDRESS:
STREET 1: 1100 MAXWELL, #522
CITY: HOBOKEN
STATE: NJ
ZIP: 07030
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0001211583
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: PO BOX 13628
STREET 2: 68 TW ALEXANDER DRIVE
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: (919) 636-4530
MAIL ADDRESS:
STREET 1: PO BOX 13628
STREET 2: 68 TW ALEXANDER DRIVE
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER COMPANY:
FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20140903
FORMER COMPANY:
FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC
DATE OF NAME CHANGE: 20021223
4
1
tm2135965-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-12-20
0
0001211583
FENNEC PHARMACEUTICALS INC.
FENC
0001787942
Goel Shubh
68 TW ALEXANDER DRIVE, PO BOX 13628
DURHAM
NC
27709
0
1
0
0
Chief Commercial Officer
Stock Option (right to buy)
4.08
2021-12-20
4
A
0
75000
0
A
2031-12-20
Common Shares
75000
75000
D
Restricted Share Unit (right to receive value of a share)
0
2021-12-20
4
A
0
37500
0
A
2031-12-20
Common Shares
37500
37500
D
On December 20, 2021, Shubh Goel was granted an incentive stock option to purchase 75,000 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
On December 20, 2021, Shubh Goel was granted restricted share units to receive 37,500 shares of the Issuer's common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
Item vests 100% upon FDA approval of PEDMARKTM.
/s/ Shubh Goel, Chief Commercial Officer
2021-12-20